Wells Fargo & Company Werewolf Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $429 Billion
- Q1 2025
A detailed history of Wells Fargo & Company transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 17,856 shares of HOWL stock, worth $19,105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,856
Previous 16,981
5.15%
Holding current value
$19,105
Previous $25,000
32.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding HOWL
# of Institutions
71Shares Held
27.4MCall Options Held
300Put Options Held
13.6K-
Ra Capital Management, L.P. Boston, MA6.14MShares$6.58 Million0.12% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.31MShares$4.61 Million6.02% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA2.51MShares$2.68 Million0.19% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.41MShares$2.58 Million0.43% of portfolio
-
Bank Of America Corp Charlotte, NC2.1MShares$2.25 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $31.6M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...